Clinical trials of antibody therapy (Q33984489)

30 July 2017

1 reference

title

Clinical trials of antibody therapy (English)

1 reference

30 July 2017

1 reference

Glennie MJ

1 reference

30 July 2017

Johnson PW

series ordinal

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

403-410

1 reference

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Antibodies stage a comeback in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Immunotherapy of endotoxemia and septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

The development of monoclonal antibodies for the therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

A review of interleukin-2 receptor antagonists in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Human antibodies by design

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

How do monoclonal antibodies induce tolerance? A role for infectious tolerance?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Mice carrying a CD20 gene disruption

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

The CD40 antigen and its ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

The TRAIL to selective tumor death

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2800%2901669-8

7 January 2021

10.1016/S0167-5699(00)01669-8

Identifiers

DOI

1 reference

30 July 2017

1 reference